AstraZeneca is reported to be in talks with U.S. drugmaker Bristol Myers Squibb about a possible megamerger, with the proposed deal size cited as roughly $400 billion. Multiple outlets say the discussions have been described in connection with a potential combination that would make the combined company one of the world’s largest pharmaceutical groups. Bloomberg reports that AstraZeneca explored an acquisition of Bristol Myers Squibb, describing the matter as confidential and attributed to people familiar with the discussions. CNBC and Financial Times also frame the situation as talks between the two companies, again referencing the potential scale of the transaction. Investing.com’s report likewise points to the Financial Times report about a $400 billion megadeal, though it does not add further specifics in the provided excerpt. The reports do not indicate whether the companies have reached any agreement or whether talks are at an early, exploratory stage. The information also does not detail regulatory expectations, potential structure, or financing terms.